ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
企業コードPROK
会社名ProKidney Corp
上場日Jun 30, 2021
最高経営責任者「CEO」Dr. Bruce Culleton, M.D.
従業員数204
証券種類Ordinary Share
決算期末Jun 30
本社所在地2000 Frontis Plaza Blvd.
都市WINSTON-SALEM
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号27103
電話番号13369997028
ウェブサイトhttps://prokidney.com/
企業コードPROK
上場日Jun 30, 2021
最高経営責任者「CEO」Dr. Bruce Culleton, M.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし